Medtronic PLC (NYSE:MDT – Get Free Report) declared a quarterly dividend on Thursday, August 20th. Investors of record on Friday, September 25th will be paid a dividend of 0.72 per share by the medical technology company on Friday, October 16th. This represents a c) dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th.
Medtronic has raised its dividend payment by an average of 0.0%per year over the last three years and has raised its dividend every year for the last 49 years. Medtronic has a dividend payout ratio of 47.8% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Medtronic to earn $6.38 per share next year, which means the company should continue to be able to cover its $2.88 annual dividend with an expected future payout ratio of 45.1%.
Medtronic Trading Down 1.8%
Shares of Medtronic stock opened at $92.45 on Friday. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The firm has a market cap of $118.33 billion, a price-to-earnings ratio of 24.79, a PEG ratio of 2.52 and a beta of 0.55. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33. The business has a 50-day moving average price of $84.12 and a 200-day moving average price of $86.01.
Medtronic Company Profile
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Further Reading
- Five stocks we like better than Medtronic
- Microsoft’s Sell-Off May Be a Gift, Not a Warning
- SK hynix Triggers $28B Defense Against Tech Selloff
- Coherent Stock Is Cooling Off Just as Its AI Thermal Opportunity Heats Up
- Moderna’s 177% Surge Has Investors Asking What Comes Next
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
